Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium [Yahoo! Finance]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: Yahoo! Finance
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced several presentations about ART12.11, Artelo's proprietary cocrystal combination drug candidate, were delivered at the th Annual International Cannabinoid Research Society (ICRS) Symposium held June 30 through July 5, 2024 in Salamanca, Spain. Andrew Yates, Ph.D., Chief Scientific Officer at Artelo, presented results from two studies entitled, “ART12.11, a Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Demonstrates a Unique Pharmacokinetic Profile,” and “ART12.11, a Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Demonstrates a Pharmacokinetic Profile Comparable with Epidiolex ® in Rats,” respectively. Matthew Jones, a member of the laboratory of Dr. Steven Laviolette at the Univers
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorGlobeNewswire
ARTL
Analyst Actions
- 8/14/24 - HC Wainwright
ARTL
Sec Filings
- 8/13/24 - Form 10-Q
- ARTL's page on the SEC website